Determining the Source of Inflammation in Patients with Elevated hs-CRP

Initial Approach to Elevated hs-CRP

The American Heart Association recommends confirming the elevated hs-CRP with repeat testing, ideally two measurements taken 2 weeks apart, to establish a stable estimate and rule out transient elevations 1, 2
For markedly elevated hs-CRP levels (≥10 mg/L), a thorough search for non-cardiovascular causes of inflammation or infection should be initiated, as recommended by the American College of Cardiology 3, 4

A complete physical examination should be performed, focusing on vascular access sites, surgical and traumatic wounds, pressure areas, signs of sinusitis or endophthalmitis, urinary catheter, and presence of diarrhea, as suggested by the Society of Critical Care Medicine 5

The American College of Gastroenterology recommends considering laboratory tests such as complete blood count with differential, blood cultures, urinalysis, and urine culture based on clinical suspicion, with a strength of evidence rated as moderate to high 5
Fecal calprotectin or lactoferrin should be considered if inflammatory bowel disease is suspected, as recommended by the American Gastroenterological Association 6

For patients with cardiovascular risk, the American Heart Association recommends assessing traditional cardiovascular risk factors and calculating an absolute risk score, with a strength of evidence rated as high 2, 4
Elevated hs-CRP may indicate increased cardiovascular risk, especially in those with intermediate risk (10-20% risk of CHD over 10 years), as suggested by the American College of Cardiology 3, 4

Imaging studies such as chest X-ray, abdominal imaging, and endoscopic assessment should be selected based on clinical suspicion, as recommended by the American College of Radiology and the American Gastroenterological Association 5, 6

Elevated hs-CRP should not be used alone to guide treatment decisions without identifying the underlying cause, as recommended by the American Heart Association and the American College of Cardiology 2, 3
In patients with known cardiovascular disease, elevated hs-CRP should not drive early management of acute coronary syndromes, as suggested by the American College of Cardiology 3

The American Heart Association/American College of Cardiology guidelines recommend that hs-CRP >10 mg/L mandates evaluation for non-cardiovascular causes, particularly infection or occult malignancy, as this level far exceeds the cardiovascular risk threshold and suggests acute systemic inflammation 7
The lipid values are protective, not inflammatory—LDL of 45 mg/dL is well below any threshold associated with cardiovascular inflammation, according to the Metabolism: Clinical and Experimental guidelines 8
Triglycerides of 27 mg/dL are remarkably low, essentially ruling out metabolic syndrome as the primary driver, as per the Metabolism: Clinical and Experimental guidelines 8

The American Heart Association/American College of Cardiology guidelines suggest calculating Framingham 10-year risk using traditional risk factors (age, sex, smoking, blood pressure, lipids) to assess cardiovascular risk 9, 7
The hs-CRP elevation should not be used for cardiovascular risk stratification until non-cardiovascular causes are excluded, as recommended by the American Heart Association/American College of Cardiology guidelines 7
If intermediate cardiovascular risk (10-20% over 10 years), elevated hs-CRP could reclassify to high risk, but only after ruling out acute inflammation, according to the American Heart Association/American College of Cardiology guidelines 9, 7

The Metabolism: Clinical and Experimental guidelines recommend targeting ≥5-10% weight reduction through lifestyle modification if overweight to address impaired glucose regulation 8, 10